Search Results 1021-1030 of 16970 for monoclonal antibody
Treatment with any monoclonal antibody within 3 months prior to Screening. Identified pre-existing ophthalmic disease that, in the judgment of the ...
The purpose of this study is to evaluate T cell and antibody immunity in patients with HER2+ breast cancer who will receive trastuzumab with standard ...
Patients with history of prior daratumumab or another anti-CD38 monoclonal antibody treatment who were not refractory or intolerant to such therapy will be able ...
Major surgery, significant trauma, wide-field radiotherapy, or therapy with monoclonal antibodies within 4 weeks before the first dose of study drug ...
testicular cancer-associated paraneoplastic encephalitis. The test, available nationally and internationally, detects the Kelch-like protein 11 antibody, or ...
Any prior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other monoclonal antibodies, antibody-drug conjugates ...
Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTC V4.03 or V5.0 for phase II part 2), any history of anaphylaxis, or ...
... monoclonal antibody-containing therapy. Note: Relapsed disease is defined as disease that has recurred ≥6 months after completion of therapy. Refractory ...
... antibody (including ipilimumab, tremelimumab or any other antibody, or drug specifically targeting T cell co stimulatory or immune checkpoint pathways).
... monoclonal antibodies. Has evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection. Note: Subjects with localized fungal infections ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The deadline to have twice the impact to advance healthcare research is May 15.